During treatment response, various EGFR-TKIs, including afatinib, erlotinib, and gefitinib, have been shown to enhance MHC class I and II expression on tumor cells, facilitating CD8+ T cell recognition and cytotoxicity [13]. This evidence concerns the gene CD8A and neoplasm.